Simulations Plus, Inc. (SLP) Analysts See $0.11 EPS

March 15, 2018 - By Ellis Scott

 Simulations Plus, Inc. (SLP) Analysts See $0.11 EPS
Investors sentiment increased to 2.06 in 2017 Q3. Its up 0.54, from 1.52 in 2017Q2. It increased, as 1 investors sold Simulations Plus, Inc. shares while 17 reduced holdings. 16 funds opened positions while 21 raised stakes. 5.43 million shares or 5.64% more from 5.14 million shares in 2017Q2 were reported.
Punch & Invest Management, Minnesota-based fund reported 407,790 shares. Redmond Asset Ltd Limited Liability Company stated it has 28,324 shares or 0.2% of all its holdings. 350 are held by Us Fincl Bank De. Cove Street Ltd Liability Com stated it has 0.14% of its portfolio in Simulations Plus, Inc. (NASDAQ:SLP). Connors Investor Incorporated has invested 0.07% in Simulations Plus, Inc. (NASDAQ:SLP). North Star Mngmt stated it has 0.24% of its portfolio in Simulations Plus, Inc. (NASDAQ:SLP). Bankshares Of New York Mellon stated it has 31,181 shares or 0% of all its holdings. Menta Limited Liability invested in 0.16% or 70,267 shares. Panagora Asset Mngmt Inc stated it has 0% in Simulations Plus, Inc. (NASDAQ:SLP). 19,300 were reported by Spark Investment Management Limited. Bahl Gaynor stated it has 0.01% in Simulations Plus, Inc. (NASDAQ:SLP). Bessemer Group invested 0% of its portfolio in Simulations Plus, Inc. (NASDAQ:SLP). Vanguard Gru owns 459,234 shares or 0% of their US portfolio. Crawford Investment Counsel holds 368,760 shares or 0.19% of its portfolio. 13,597 are owned by Blair William And Co Il.

Since September 27, 2017, it had 0 buys, and 3 insider sales for $887,166 activity.

Analysts expect Simulations Plus, Inc. (NASDAQ:SLP) to report $0.11 EPS on April, 9.They anticipate $0.04 EPS change or 57.14 % from last quarter’s $0.07 EPS. SLP’s profit would be $1.90 million giving it 36.93 P/E if the $0.11 EPS is correct. After having $0.10 EPS previously, Simulations Plus, Inc.’s analysts see 10.00 % EPS growth. The stock increased 1.56% or $0.25 during the last trading session, reaching $16.25. About 28,972 shares traded. Simulations Plus, Inc. (NASDAQ:SLP) has risen 48.65% since March 15, 2017 and is uptrending. It has outperformed by 31.95% the S&P500.

Simulations Plus, Inc. develops and sells drug discovery and development software for mechanistic modeling and simulation. The company has market cap of $281.01 million. The firm offers GastroPlus, which simulates the absorption, pharmacokinetics , and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments. It has a 46.43 P/E ratio. It also provides PKPlus, a standalone program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for NCA and compartmental PK modelling; ADMET Predictor, a chemistry computer program, which takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher that integrates with MedChem Studio and ADMET Predictor.

More notable recent Simulations Plus, Inc. (NASDAQ:SLP) news were published by: which released: “DILIsym Services Inc., a Simulations Plus Company, Releases DILIsym® Version 7A” on January 11, 2018, also with their article: “Simulations Plus’ (SLP) CEO Walt Woltosz on Q4 2017 Results – Earnings Call …” published on November 15, 2017, published: “DILIsym Services Inc., a Simulations Plus Company, Releases DILIsym” on August 08, 2017. More interesting news about Simulations Plus, Inc. (NASDAQ:SLP) were released by: and their article: “Simulations Plus, Inc. (SLP) Ex-Dividend Date Scheduled for November 10, 2017” published on November 09, 2017 as well as‘s news article titled: “Simulations Plus Announces Senior Management Changes” with publication date: August 31, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: